Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of 68Ga-PSMA Production Methods
NCT04685811Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium ga-68 gozetotide in prostate adenocarcinoma, sponsored by Weill Cornell Medicine. Primary endpoints: Evaluate Equivalence Between 68GA-PSMA-cyclotron and 68Ga-PSMA-generator Across Varying Pathologic Lesions, Evaluate Equivalence Between 68GA-PSMA-cyclotron and 68Ga-PSMA-generator Across Varying Average SUV Max-pathologic Regions and 1 more. Started Dec 2020; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT04685811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04685811.